| Product Unit Size | Cost | Quantity | Stock |
|---|
BAY80-6946 is an inhibitor of p110α PI3K that exhibits anticancer chemotherapeutic activity. BAY80-6946 is currently in clinical trials and shows some benefit in the treatment of pancreatic cancer. In cellular and animal models of multiple myeloma, BAY80-6946 inhibits cell cycle progression, induces apoptosis, and inhibits cell proliferation and tumor growth.
| Cas No. | 1402152-13-9 |
|---|---|
| Purity | ≥98% |
| Formula | C23H30Cl2N8O4 |
| Formula Wt. | 553.45 |
| Chemical Name | 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide;dihydrochloride |
| IUPAC Name | 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamide;dihydrochloride |
| Synonym | Copanlisib HCl, BAY80-6946 HCl; Copanlisib dihydrochloride; UNII-03ZI7RZ52O; 03ZI7RZ52O |
| Solubility | Soluble in water (20 mg/mL). |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Glauer J, Pletz N, Schön M, et al. A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo. Blood Cancer J. 2013 Sep 6;3:e141. PMID: 24013662.
Cheng H, Merika E, Syrigos KN, et al. Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP. 2011 Jul 8;12(4):334-8. PMID: 21737890.
